Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases.

@article{citeulike:2230173, abstract = {Advanced glycation end products (AGEs) are formed by the nonenzymatic Maillard reaction between sugars and proteins. Low-molecular weight AGEs are filtered by renal glomeruli and then reabsorbed and metabolized by proximal tubule cells (PTCs). High-molecular weight AGEs are also delivered to PTCs in proteinuric states. In patients with diabetes, AGE generation is increased, and the actions of AGEs on PTCs are likely involved in the pathogenesis of diabetic nephropathy. In patients with chronic renal failure (CRF), reduced renal metabolism of AGEs likely accounts for the accumulation of AGEs in serum, leading to uremic complications including dialysis-related amyloidosis. AGE precursors such as reactive carbonyl compounds also accumulate in the sera of patients with CRF. It is likely that PTCs take up AGEs and AGE precursors via specific endocytotic receptors or transporters. Megalin is a multiligand endocytotic receptor that is abundantly expressed on PTCs. There is evidence that megalin is involved in the cellular uptake and degradation of AGEs. We previously reported a cell therapy model involving implantation of megalin-expressing cells into experimental mice with renal failure for elimination of uremic toxin proteins. Further studies are needed to clarify the molecular mechanisms of the metabolism of AGEs and their precursors to develop a strategy for the treatment of diabetic nephropathy and uremic complications of CRF.}, address = {Department of Applied Molecular Medicine, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan. akisaito@med.niigata-u.ac.jp}, author = {Saito, A. and Takeda, T. and Sato, K. and Hama, H. and Tanuma, A. and Kaseda, R. and Suzuki, Y. and Gejyo, F. }, citeulike-article-id = {2230173}, doi = {10.1196/annals.1333.072}, issn = {0077-8923}, journal = {Ann N Y Acad Sci}, month = {June}, pages = {637--643}, posted-at = {2008-01-14 11:56:22}, priority = {2}, title = {Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases.}, url = {http://dx.doi.org/10.1196/annals.1333.072}, volume = {1043}, year = {2005} }

TY - JOUR ID - citeulike:2230173 L3 - citeulike-article-id:2230173 TI - Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. JF - Ann N Y Acad Sci VL - 1043 SP - 637 EP - 643 AD - Department of Applied Molecular Medicine, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Niigata, 951-8510, Japan. akisaito@med.niigata-u.ac.jp SN - 0077-8923 N2 - Advanced glycation end products (AGEs) are formed by the nonenzymatic Maillard reaction between sugars and proteins. Low-molecular weight AGEs are filtered by renal glomeruli and then reabsorbed and metabolized by proximal tubule cells (PTCs). High-molecular weight AGEs are also delivered to PTCs in proteinuric states. In patients with diabetes, AGE generation is increased, and the actions of AGEs on PTCs are likely involved in the pathogenesis of diabetic nephropathy. In patients with chronic renal failure (CRF), reduced renal metabolism of AGEs likely accounts for the accumulation of AGEs in serum, leading to uremic complications including dialysis-related amyloidosis. AGE precursors such as reactive carbonyl compounds also accumulate in the sera of patients with CRF. It is likely that PTCs take up AGEs and AGE precursors via specific endocytotic receptors or transporters. Megalin is a multiligand endocytotic receptor that is abundantly expressed on PTCs. There is evidence that megalin is involved in the cellular uptake and degradation of AGEs. We previously reported a cell therapy model involving implantation of megalin-expressing cells into experimental mice with renal failure for elimination of uremic toxin proteins. Further studies are needed to clarify the molecular mechanisms of the metabolism of AGEs and their precursors to develop a strategy for the treatment of diabetic nephropathy and uremic complications of CRF. AU - Saito, A AU - Takeda, T AU - Sato, K AU - Hama, H AU - Tanuma, A AU - Kaseda, R AU - Suzuki, Y AU - Gejyo, F PY - 2005/06// UR - http://dx.doi.org/10.1196/annals.1333.072 ER -